Physician profile
Thelma L Young-Bolden
NPI 1316910367
$5,583.51
in general payments reported to CMS, 2019-2025
21 companies · $1,528 in 2025
The $1,528 reported for 2025 was more than what 92% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $999 · 2023: $1,258 · 2024: $1,576 · 2025: $1,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $975.67 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $845.12 | 2021-2025 | Caplyta |
| Alkermes, INC. | $793.93 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $548.54 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $505.45 | 2021-2025 | |
| Axsome Therapeutics, INC. | $406.82 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $377.54 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $292.22 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $249.61 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $173.18 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $117.79 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Noven Therapeutics, LLC | $52.11 | 2024-2025 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $49.85 | 2022-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $47.86 | 2024-2025 | Qelbree |
| Gilead Sciences, INC. | $36.63 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $35.94 | 2023 | Quviviq |
| Indivior INC. | $20.36 | 2023 | Perseris |
| Ucb, INC. | $15.06 | 2023 | Briviact |
| Owp Pharmaceuticals, INC. | $14.97 | 2024 | Subvenite |
| Phathom Pharmaceuticals, INC. | $13.52 | 2024 | Voquezna |
| Corium, LLC | $11.34 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thelma Young-Bolden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.